New paradigm for stage III melanoma: from surgery to adjuvant treatment.

New paradigm for stage III melanoma: from surgery to adjuvant treatment.

Publication date: Aug 14, 2019

Recently the 8th version of the American Joint Committee on Cancer (AJCC) classification has been introduced, and has attempted to define a more accurate and precise definition of prognosis in line with the major progresses in understanding the biology and pathogenesis of melanoma. This new staging system introduces major changes in the stage III staging system. Indeed, surgical practice is changing in stage III patients, since, according to recent evidence, there is no survival benefit in radical lymph node dissection following a positive sentinel lymph node dissection. Therefore, some patients currently staged IIIB-C after dissection could be downgraded to IIIA (as in the case of patients with metastatic non-sentinel lymph nodes) since many completion lymph node dissections will no longer be performed. Moreover, new and effective targeted and immune strategies are being introduced in the pharmacological armamentarium in the adjuvant setting, showing major efficacy.

This article provides the authors’ personal view on the above-mentioned topics.

Open Access PDF

Ascierto, P.A., Borgognoni, L., Botti, G., Guida, M., Marchetti, P., Mocellin, S., Muto, P., Palmieri, G., Patuzzo, R., Quaglino, P., and , Stanganelli. New paradigm for stage III melanoma: from surgery to adjuvant treatment. 23773. 2019 J Transl Med (17):1.

Concepts Keywords
Adjuvant III melanoma
AJCC Pathogenesis melanoma
Dissection Surgery
Lymph Node Medicine
Lymph Node Dissection Medical specialties
Melanoma Clinical medicine
Metastatic Cancer
Paradigm Oncology
Pathogenesis RTT
Pharmacological Surgical oncology
Prognosis Lymphadenectomy
Sentinel Lymph Node Sentinel lymph node
Sentinel Lymph Nodes Melanoma
Cancer staging

Semantics

Type Source Name
gene UNIPROT ADI1
drug DRUGBANK Bismuth subgallate
drug DRUGBANK Gold
gene UNIPROT LARGE1
drug DRUGBANK Succimer
gene UNIPROT EXOG
disease MESH multi
gene UNIPROT MCHR2
gene UNIPROT CXCL2
gene UNIPROT CNR1
gene UNIPROT ELK3
gene UNIPROT EPHB1
gene UNIPROT SLC6A2
gene UNIPROT PDC
gene UNIPROT EGR3
gene UNIPROT PDPN
gene UNIPROT MARK1
gene UNIPROT TNIP1
disease MESH micrometastases
gene UNIPROT SET
gene UNIPROT MS4A2
gene UNIPROT KIDINS220
gene UNIPROT EMD
drug DRUGBANK Trametinib
drug DRUGBANK Dabrafenib
gene UNIPROT MAL
gene UNIPROT MRTFA
gene UNIPROT TIRAP
gene UNIPROT CD8A
gene UNIPROT BRAF
drug DRUGBANK Vemurafenib
disease DOID cutaneous melanoma
gene UNIPROT MENT
drug DRUGBANK Trestolone
disease MESH death
drug DRUGBANK Pembrolizumab
drug DRUGBANK Natural alpha interferon
drug DRUGBANK Ipilimumab
drug DRUGBANK Nivolumab
gene UNIPROT TNFSF14
gene UNIPROT PTPRF
gene UNIPROT RET
gene UNIPROT PDGFB
disease MESH recurrence
gene UNIPROT DEPP1
gene UNIPROT GOPC
gene UNIPROT NODAL
disease MESH metastases
gene UNIPROT RAN
drug DRUGBANK Ranitidine
drug DRUGBANK Coenzyme M
gene UNIPROT ABCC8
disease DOID noma
disease MESH noma
gene UNIPROT PSD4
disease MESH tic
disease MESH classi
pathway BSID Reproduction
gene UNIPROT SCN8A
disease DOID Cancer
disease MESH Cancer
pathway BSID Melanoma
disease DOID melanoma
disease MESH melanoma

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *